AdaptHealth (AHCO) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue was $806 million, up 1.6% year-over-year, driven by growth in sleep and respiratory businesses, while diabetes revenue declined due to payer and channel shifts.

• Net income for Q2 2024 was $19.4 million, a 39% increase from Q2 2023.

• Adjusted EBITDA for Q2 2024 was $165.3 million (20.5% margin), down from $171.0 million (21.6% margin) in Q2 2023.

• Free cash flow for Q2 2024 was $116.7 million, a significant increase from $3.7 million in Q2 2023, aided by claims processing resolution.

• Leadership changes included the appointment of Suzanne Foster as CEO and other executive transitions.

Financial highlights

• Six-month net revenue was $1.60 billion, up 3.9% year-over-year; net income for Q2 was $19.4 million.

• Sleep revenue grew 6.5% to $322.4 million; respiratory revenue increased 4.6% to $161.2 million.

• Diabetes revenue declined by $17.7 million year-over-year to $151.2 million due to tough CGM comparables and pump timing.

• Adjusted EBITDA margin for Q2 2024 was 20.5%, down from 21.6% in Q2 2023.

• Free cash flow reached $116.7 million, exceeding the $94 million target.

Outlook and guidance

• Q3 revenue expected to be flat sequentially, with adjusted EBITDA margin at 20.0% and free cash flow of at least $30 million.

• Full-year 2024 guidance: net revenue $3.255–$3.315 billion, adjusted EBITDA $660–$700 million, free cash flow $160–$180 million.

• Diabetes revenue expected to rebound in the second half as new pump integrations and pharmacy channel expansion progress.

• Management expects operating cash flows, existing cash, and available credit to be sufficient for at least the next twelve months.

• Inflationary pressures and payer channel shifts, especially in diabetes, are expected to continue impacting results.